Antibiotics for human toxoplasmosis: a systematic review of randomized trials

References

• Dumètre A, Dardè ML. How to detect Toxoplasma gondii oocysts in environmental samples? FEMS Microbiol Rev. 2003;27:651–61.
   PubMed Web of Science ®Google Scholar
• Roberts T, Murrell KD, Marks S. Economic losses caused by foodborne parasitic diseases. Parasitol Today. 1994;10:419–23.
   PubMedGoogle Scholar
• Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15:211–22.
   PubMed Web of Science ®Google Scholar
• Elsheikha HM. Congenital toxoplasmosis: priorities for further health promotion action. Public Health. 2008;122:335–53.
   PubMed Web of Science ®Google Scholar
• Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis. 2012;44:805–14.
   PubMed Web of Science ®Google Scholar
• McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis. 1987;9:754–74.
   PubMedGoogle Scholar
• Georgiev VS. Management of toxoplasmosis. Drugs. 1994;48:179–88.
   PubMed Web of Science ®Google Scholar
• Remington JS, McLeod R. Toxoplasmosis. In: Remington JS, Klein JO, (eds.) Infectious diseases of the fetus and newborn infant. 4th ed. Philadelphia: WB Saunders; 1995. p. 140.
   Google Scholar
• Wong SY, Remington JS. Toxoplasmosis in pregnancy. Clin Infect Dis. 1994;18:853–61; quiz 862.
   PubMed Web of Science ®Google Scholar
• Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. BMJ. 1999;318:1511–4.
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1–17.
   PubMed Web of Science ®Google Scholar
• Holland GN, Crespi CM, ten Dam-van Loon N, Charonis AC, Yu F, Bosch-Driessen LH, et al.. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol. 2008;145:1007–13.
   PubMed Web of Science ®Google Scholar
• Tabbara KF. Ocular toxoplasmosis: toxoplasmic retinochoroiditis. Int Ophthalmol Clin. 1995;35:15–29.
   PubMedGoogle Scholar
• Ruskin J, Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med. 1976;84:193–9.
   PubMed Web of Science ®Google Scholar
• Bertoli F, Espino M, Arosemena, Fishback JRJL, Frenkel JK. A spectrum in the pathology of toxoplasmosis in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1995;119:214–24.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Remington JS. Immunopathogenesis of toxoplasmic encephalitis. J Infect Dis. 1994;170:1057–67.
   PubMed Web of Science ®Google Scholar
• Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, et al.. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol. 1999;180:410–5.
   PubMed Web of Science ®Google Scholar
• Araujo FG, Shepard RM, Remington JS. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1991;10:519–24.
   PubMed Web of Science ®Google Scholar
• Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother. 1995;39:1530–7.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Remington JS. Toxoplasma gondii. In: Mandell GL, Benntt JE, Dolin R, (eds.) Principles and practice of infectious disease. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 2858–88.
   Google Scholar
• Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
   PubMed Web of Science ®Google Scholar
• Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al.. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study. Clin Infect Dis. 2002;34:1243–50.
   PubMed Web of Science ®Google Scholar
• Alavi SM, Alavi L. Treatment of toxoplasmic lymphadenitis with co-trimoxazole: double-blind, randomized clinical trial. Int J Infect Dis. 2010;14 Suppl 3:e67–9.
   Web of Science ®Google Scholar
• Kongsaengdao S, Samintarapanya K, Oranratnachai K, Prapakarn W, Apichartpiyakul C. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. J Int Assoc Physicians AIDS Care (Chic). 2008;7:11–6.
   Google Scholar
• Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, et al.. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998;42:1346–9.
   PubMed Web of Science ®Google Scholar
• Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al.. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992;116:33–43.
   PubMed Web of Science ®Google Scholar
• Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22:268–75.
   PubMed Web of Science ®Google Scholar
• Acers TE. Toxoplasmic retinochoroiditis: a double-blind therapeutic study. Arch Ophthalmol. 1964;71:58–62.
   PubMed Web of Science ®Google Scholar
• Silveira C, Belfort R, Muccioli C, Holland GN, Victora CG, Horta BL, et al.. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41–6.
   PubMed Web of Science ®Google Scholar
• Perkins ES, Schofield PB, Smith CH. Treatment of uveitis with pyrimethamine (daraprim). Br J Ophthalmol. 1956;40:577–86.
   PubMedGoogle Scholar
• Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39–46.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, et al.. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134–41.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, et al.. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876–82.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al.. A prospective, randomized trial of pyrimethamine and azithromycin vs. pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34–40.
   PubMed Web of Science ®Google Scholar
• Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit. 2012;18:CR296–302.
   Web of Science ®Google Scholar
• Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LM, Tan HK, Wallon M, et al.. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis. 2008;2:e277.
   PubMed Web of Science ®Google Scholar